Efficacy, safety, and B-cell depletion capacity of three rituximab dosing regimens in the treatment of moderate-to-severe pemphigus vulgaris and pemphigus foliaceus: a 52-week clinical trial
Published: 2 May 2025| Version 1 | DOI: 10.17632/jd8hp2377n.1
Contributors:
Shan Cao, , , , , , , Qing Yang, , , , Description
Supplemental material for "Efficacy, safety, and B-cell depletion capacity of three rituximab dosing regimens in the treatment of moderate-to-severe pemphigus vulgaris and pemphigus foliaceus: a 52-week clinical trial".
Files
Institutions
Shandong Provincial Institute of Dermatology and Venereology
Categories
Rituximab, Pemphigus